Eko Murmur Analysis Software (EMAS) vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
VS
by Elucid

AI Verdict

Tool A, Eko Murmur Analysis Software, focuses on the early detection and differentiation of heart murmurs using acoustic data from digital stethoscopes. In contrast, Tool B, ElucidVivo A.3, specializes in quantitative analysis of arterial plaque composition from CT angiography images to aid in atherosclerosis patient stratification. While both are FDA-cleared AI tools for cardiovascular care, they address distinct clinical problems with different data modalities, making them complementary rather than directly comparable.

Choose Eko Murmur Analysis Software (EMAS) if…

Choose Eko Murmur Analysis Software (EMAS) if you are a clinician needing an AI-powered tool for real-time, point-of-care detection and differentiation of heart murmurs during physical examinations or telehealth consultations. This solution is ideal for early screening in both adult and pediatric patients, providing immediate clinical decision support to identify potential cardiac and pulmonary conditions.

View Eko Murmur Analysis Software (EMAS) →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients and optimize treatment decisions. This system is best suited for specialists who need detailed visualization and objective measurements of plaque characteristics for risk assessment and interventional planning.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Eko Murmur Analysis Software (EMAS) ElucidVivo A.3
Pricing Starts at $119.99 per year for eko+ membership; enterprise solutions require contacting sales. Unknown
Deployment Cloud-based, Mobile App Cloud and on-premise secure deployment.
BAA Available Yes AI-estimated Unknown
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Eko Murmur Analysis Software (EMAS)

Eko Murmur Analysis Software (EMAS) offers a highly accessible and intuitive mobile application experience with direct integration to a digital stethoscope, making it easy for clinicians to adopt and use in various settings. ElucidVivo A.3, while powerful, is a more specialized imaging analysis software that likely requires deeper integration into existing hospital IT infrastructure and imaging workflows, potentially presenting a steeper learning curve.

Clinical Value

ElucidVivo A.3

While EMAS provides valuable early detection for murmurs, ElucidVivo A.3 offers a more advanced and quantitative analysis of arterial plaque composition and stability, validated against histology. This provides deeper, more actionable insights for patient stratification and optimizing treatment decisions in complex cardiovascular disease management.

Pricing & Value

Eko Murmur Analysis Software (EMAS)

EMAS provides clear, tiered pricing with a free entry point for basic AI analysis, allowing users to experience the tool before committing to paid subscriptions. ElucidVivo A.3's 'contact for pricing' lacks transparency, making it difficult for potential users to assess its immediate value proposition without direct engagement.

Enterprise Readiness

Eko Murmur Analysis Software (EMAS)

EMAS explicitly states its HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical assurances for enterprise adoption and data security. While ElucidVivo A.3's compliance is implied and it integrates with PACS/EMR, the explicit declarations from Tool A provide greater clarity and confidence for institutional deployment.

Innovation

ElucidVivo A.3

Both tools are innovative in their respective domains. However, ElucidVivo A.3 demonstrates a higher level of innovation by providing quantitative, histology-validated insights into arterial plaque composition and stability from CT images, including the derivation of FFRct. This addresses a more complex diagnostic challenge and offers more profound implications for personalized cardiovascular risk assessment and treatment strategies.

Support & Docs

Eko Murmur Analysis Software (EMAS)

Eko Devices offers a well-documented and easily accessible support ecosystem, including a comprehensive Help Center, user manuals, FAQs, and direct contact options for both individual and enterprise users. Elucid Bioimaging's available information primarily focuses on clinical and regulatory aspects, with no explicit details on user-facing support and documentation.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Eko Murmur Analysis Software (EMAS) ElucidVivo A.3
Name Eko Murmur Analysis Software (EMAS) ElucidVivo A.3
Company Eko Devices Elucid Bioimaging
Description FDA-cleared AI tool that integrates with Eko digital stethoscopes to detect and differentiate heart murmurs in adult and pediatric patients, providing clinical decision support for early detection of heart and lung disease. FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology.
Specialties Cardiology, Internal Medicine, Pediatrics Cardiology, Radiology, Vascular Surgery
Key Features FDA-cleared AI for murmur detection; Analyzes heart sound (PCG) and optional ECG data; Differentiates innocent and structural heart murmurs; Provides clinical decision support; Integrates with Eko digital stethoscopes (CORE 500, DUO, CORE); Mobile app for recording, playback, annotation, and saving; Wireless Bluetooth connectivity to mobile devices; PDF report generation and sharing (EHR compatible) AI-powered quantitative analysis of arterial plaque; Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; Visualizes lesion-level plaque composition; Provides 3D visualization of highlighted vessels; Offers rotatable curved MPR vessel views and cross-sections; Aids in stratifying patients with atherosclerosis; Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity; Validated on ground-truth histology

Videos

Demos, reviews, and walkthroughs featuring Eko Murmur Analysis Software (EMAS) and ElucidVivo A.3.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Eko Murmur Analysis Software (EMAS) is an FDA-cleared AI tool designed to detect and differentiate heart murmurs in adult and pediatric patients, providing clinical decision support for early detection of heart and lung disease. ElucidVivo A.3 is an FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist physicians in atherosclerosis patient stratification and optimize treatment decisions.
EMAS analyzes heart sound (PCG) and optional ECG data captured using Eko digital stethoscopes. ElucidVivo A.3 performs quantitative analysis of arterial plaque composition and stability from CT angiography images.
Eko Murmur Analysis Software is designed for Cardiology, Internal Medicine, and Pediatrics. ElucidVivo A.3 is intended for use in Cardiology, Radiology, and Vascular Surgery.
EMAS provides FDA-cleared AI for murmur detection, differentiating innocent and structural heart murmurs, and identifying their timing and character. ElucidVivo A.3 offers AI-powered quantitative analysis of arterial plaque, objectively quantifying Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, and can derive fractional flow reserve (FFRct).
Eko Murmur Analysis Software is FDA-cleared, explicitly states HIPAA compliance, and has a Business Associate Agreement (BAA) available. ElucidVivo A.3 is also FDA-cleared, with HIPAA compliance implied by its intended use in the U.S. healthcare system, but a BAA is not explicitly stated in the provided information.

Backers

Who funded each tool's parent company.

Eko Murmur Analysis Software (EMAS)

AI Tool Finder
AI-powered search. Results may not be comprehensive.